These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 12792982)

  • 1. Effects of eparlestat on plasma levels of advanced glycation end products in patients with type 2 diabetes.
    Nakamura N; Yamazaki K; Satoh A; Urakaze M; Kobayashi M; Yamabe H; Osawa H; Shirato K; Sugawara T; Nakamura M; Tamura M; Okumura K
    In Vivo; 2003; 17(2):177-80. PubMed ID: 12792982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine.
    Kawai T; Takei I; Tokui M; Funae O; Miyamoto K; Tabata M; Hirata T; Saruta T; Shimada A; Itoh H
    J Diabetes Complications; 2010; 24(6):424-32. PubMed ID: 19716319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
    Hamada Y; Nakamura J; Naruse K; Komori T; Kato K; Kasuya Y; Nagai R; Horiuchi S; Hotta N
    Diabetes Care; 2000 Oct; 23(10):1539-44. PubMed ID: 11023149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension.
    Busch M; Franke S; Wolf G; Brandstädt A; Ott U; Gerth J; Hunsicker LG; Stein G;
    Am J Kidney Dis; 2006 Oct; 48(4):571-9. PubMed ID: 16997053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes.
    Scharnagl H; Stojakovic T; Winkler K; Rosinger S; März W; Boehm BO
    Exp Clin Endocrinol Diabetes; 2007 Jun; 115(6):372-5. PubMed ID: 17701882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An inhibitor of advanced glycation end product formation reduces N epsilon-(carboxymethyl)lysine accumulation in glomeruli of diabetic rats.
    Nakamura S; Tachikawa T; Tobita K; Aoyama I; Takayama F; Enomoto A; Niwa T
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S68-71. PubMed ID: 12612956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement].
    Shimada H; Miki T; Kyogoku I; Kawagishi T; Inaba M; Okuno Y; Nishizawa Y; Morii H
    No To Shinkei; 1998 Sep; 50(9):817-20. PubMed ID: 9789304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice.
    Tanimoto M; Gohda T; Kaneko S; Hagiwara S; Murakoshi M; Aoki T; Yamada K; Ito T; Matsumoto M; Horikoshi S; Tomino Y
    Metabolism; 2007 Feb; 56(2):160-7. PubMed ID: 17224327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma glycooxidation protein products in type 2 diabetic patients with nephropathy.
    Piwowar A; Knapik-Kordecka M; Szczecińska J; Warwas M
    Diabetes Metab Res Rev; 2008 Oct; 24(7):549-53. PubMed ID: 18613218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severity of diabetic microvascular complications is associated with a low soluble RAGE level.
    Grossin N; Wautier MP; Meas T; Guillausseau PJ; Massin P; Wautier JL
    Diabetes Metab; 2008 Sep; 34(4 Pt 1):392-5. PubMed ID: 18701333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased serum levels of advanced glycation end products in NIDDM patients with diabetic complications.
    Ono Y; Aoki S; Ohnishi K; Yasuda T; Kawano K; Tsukada Y
    Diabetes Care; 1998 Jun; 21(6):1027. PubMed ID: 9614627
    [No Abstract]   [Full Text] [Related]  

  • 12. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
    Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
    Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products.
    Sebeková K; Gazdíková K; Syrová D; Blazícek P; Schinzel R; Heidland A; Spustová V; Dzúrik R
    J Hum Hypertens; 2003 Apr; 17(4):265-70. PubMed ID: 12692571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and prognostic value of advanced glycation end-products in chronic heart failure.
    Hartog JW; Voors AA; Schalkwijk CG; Scheijen J; Smilde TD; Damman K; Bakker SJ; Smit AJ; van Veldhuisen DJ
    Eur Heart J; 2007 Dec; 28(23):2879-85. PubMed ID: 17986469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes.
    Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
    Diabetes Metab Res Rev; 2008 Feb; 24(2):109-14. PubMed ID: 17694504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced glycation end products accumulate in the reproductive tract of men with diabetes.
    Mallidis C; Agbaje IM; Rogers DA; Glenn JV; Pringle R; Atkinson AB; Steger K; Stitt AW; McClure N
    Int J Androl; 2009 Aug; 32(4):295-305. PubMed ID: 18217985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial.
    Engelen L; Persson F; Ferreira I; Rossing P; Hovind P; Teerlink T; Stehouwer CD; Parving HH; Schalkwijk CG
    Nephrol Dial Transplant; 2011 Nov; 26(11):3573-7. PubMed ID: 21385863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased levels of advanced glycation end-products in patients with Gilbert syndrome.
    Kalousová M; Novotny L; Zima T; Braun M; Vítek L
    Cell Mol Biol (Noisy-le-grand); 2005 Sep; 51(4):387-92. PubMed ID: 16309589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nepsilon-(carboxymethyl)lysine, Nepsilon-(carboxyethyl)lysine and vascular cell adhesion molecule-1 (VCAM-1) in relation to peritoneal glucose prescription and residual renal function; a study in peritoneal dialysis patients.
    van de Kerkhof J; Schalkwijk CG; Konings CJ; Cheriex EC; van der Sande FM; Scheffer PG; ter Wee PM; Leunissen KM; Kooman JP
    Nephrol Dial Transplant; 2004 Apr; 19(4):910-6. PubMed ID: 15031349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy.
    Zhou H; Tan KC; Shiu SW; Wong Y
    Nephrol Dial Transplant; 2008 Mar; 23(3):927-33. PubMed ID: 18065800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.